Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04743635
Registration number
NCT04743635
Ethics application status
Date submitted
3/02/2021
Date registered
8/02/2021
Titles & IDs
Public title
CONtrolled Focal Fibrous Band Release Method Study
Query!
Scientific title
CONtrolled Focal Fibrous Band Release Method Study
Query!
Secondary ID [1]
0
0
CP-10472
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CONFFIRM
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cellulite
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Avéli device
Experimental: Targeted Verifiable Subcision (TVS) with the Avéli device, mITT - Modified intent to treat population (n=68). The modified intent to treat population was used to evaluate effectiveness.
The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks
Experimental: Targeted Verifiable Subcision (TVS) with the Avéli device, Roll-in - The roll-in population (n=6) was excluded from the effectiveness analyses. For Investigators that have not previously performed an Avéli procedure, two (2) participants were classified as roll-in participants. The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks
Treatment: Devices: Avéli device
Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Mean Change From Baseline to 3 Months in Cellulite Severity Scale (CSS) Score for Participants
Query!
Assessment method [1]
0
0
The CSS includes a 6-point (range of 0-5) and will be determined by 3 independent, blinded physician assessors of images obtained before and 3-months after treatment.
CSS Scale TOTAL CSS SCORE: = (PART A + PART B) - 1
PART A- Number of evident depressions 0 None
1. Mild (=4 depressions)
2. Moderate (5 to 9 depressions)
3. Severe (= 10 depressions) PART B - Average depth of depressions
0 None
1. Mild (1-2 mm)
2. Moderate (3-4 mm)
3. Severe (=5 mm)
Query!
Timepoint [1]
0
0
3 months
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Improvement as Assessed Using Global Aesthetic Improvement Scale (GAIS) at 3 Months
Query!
Assessment method [1]
0
0
The GAIS score was determined by blinded, independent evaluators. The GAIS scale counted if at least two of the three evaluators selected it, otherwise the median between the three was counted. A participant is considered improved if the GAIS assessment is improved (1), much improved (2) or very much improved (3). The hierarchal endpoint is met if the lower bound of the 2-sided 95% confidence interval is greater than or equal to 0.6.
Scale: -3:very much worse, the treated area appearance is worse than before procedure, -2: much worse, the treated area appearance is significantly worse than before procedure, -1: worsened, the treated area appearance is slightly worse than before procedure, 0:no change, the treated area appearance is the same, +1: improved, noticeable improvement in appearance of the treated areas, but subtle, +2: much improved, significant improvement in appearance in the treated areas, +3: very much improved, optimal cosmetic result in the treated areas.
Query!
Timepoint [1]
0
0
3 months
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Improvement as Assessed Using Global Aesthetic Improvement Scale (GAIS) at 12 Months
Query!
Assessment method [2]
0
0
The GAIS score was determined by blinded, independent evaluators. The GAIS scale counted if at least two of the three evaluators selected it, otherwise the median between the three was counted. A participant is considered improved if the GAIS assessment is improved (1), much improved (2) or very much improved (3).
Scale: -3: very much worse, the treated area appearance is worse than before procedure, -2: much worse, the treated area appearance is significantly worse than before procedure, -1: worsened, the treated area appearance is slightly worse than before procedure, 0:no change, the treated area appearance is the same, +1: improved, noticeable improvement in appearance of the treated areas, but subtle, +2: much improved, significant improvement in appearance in the treated areas, +3: very much improved, optimal cosmetic result in the treated areas.
Query!
Timepoint [2]
0
0
12 Months
Query!
Secondary outcome [3]
0
0
The Mean Change From Baseline to 12 Months in Cellulite Severity Scale (CSS) Score for Participants
Query!
Assessment method [3]
0
0
The CSS includes a 6-point (range of 0-5) and will be determined by 3 independent, blinded physician assessors of images obtained before and 3-months after treatment.
CSS Scale TOTAL CSS SCORE: = (PART A + PART B) - 1
PART A- Number of evident depressions 0 None
1. Mild (=4 depressions)
2. Moderate (5 to 9 depressions)
3. Severe (= 10 depressions) PART B - Average depth of depressions
0 None
1. Mild (1-2 mm)
2. Moderate (3-4 mm)
3. Severe (=5 mm)
Query!
Timepoint [3]
0
0
12 months
Query!
Secondary outcome [4]
0
0
The Percentage of Patients Satisfied With Their Results at 3 Months
Query!
Assessment method [4]
0
0
Participants were asked to rate their satisfaction with their results (from very satisfied to very dissatisfied) in an online questionnaire at 3 months. The outcome measure reports the percentage of participants satisfied with their results at 3 months. The Site was blinded to the questionnaire data. The sponsor was only unblinded after the data analyses.
The lower bound of the 2-sided 95% confidence interval had to be greater than or equal to 0.6.
Query!
Timepoint [4]
0
0
3 month
Query!
Secondary outcome [5]
0
0
The Number of Patients Satisfied With Their Results at 12 Months
Query!
Assessment method [5]
0
0
Participants were asked to rate their satisfaction with their results (from very satisfied to very dissatisfied) in an online questionnaire at 12 months. The outcome measure reports the number of participants satisfied with their results at 12 months. The Site was blinded to the questionnaire data. The sponsor was only unblinded after the data analyses.
Query!
Timepoint [5]
0
0
12 Months
Query!
Eligibility
Key inclusion criteria
* Moderate to severe cellulite
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Body Mass Index =30.0
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/01/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
4/03/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
74
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Clinical Site #7 - Southport
Query!
Recruitment hospital [2]
0
0
Clinical Site #9 - Toowoomba
Query!
Recruitment postcode(s) [1]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [2]
0
0
4350 - Toowoomba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Louisiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Revelle Aesthetics, Inc
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study to evaluate the safety and effectiveness of the Avéli medical device to reduce the appearance of cellulite.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04743635
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Dr. G. William Stevens, MD
Query!
Address
0
0
Marina Plastic Surgery
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Plan to share Executive Summary of Protocol. No formal, separate SAP for this study.
Supporting document/s available: Study protocol
Query!
When will data be available (start and end dates)?
Will post Protocol Executive Summary on June 14, 2022. It will be available indefinitely.
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/35/NCT04743635/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/35/NCT04743635/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04743635